Founded in 2018, Kousai Bio develops and industrializes therapeutic dendritic cell (DC) vaccines using its proprietary Eco-DCVax platform
Founded in 2018, Kousai Bio develops and industrializes therapeutic dendritic cell (DC) vaccines using its proprietary Eco-DCVax platform. Its lead candidate KSD-101 targets EBV-related hematologic malignancies and solid tumors, with additional programs for cancers including pancreatic and renal cancer. The company is also developing DC vaccine approaches for chronic viral infections and autoimmune diseases.